Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Piracetam
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : UCB Pharma S.A
Deal Size : Undisclosed
Deal Type : Partnership
M8 Pharmaceuticals and UCB Partner for Central Nervous System and Respiratory Portfolio in Mexico
Details : According to IQVIA, the portfolio has annual sales of approximately $26 million dollars and includes drugs such as: ATARAX®, NOOTROPIL®, XUZAL®, and VIRLIX®.
Brand Name : Nootropil
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 22, 2021
Lead Product(s) : Piracetam
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : UCB Pharma S.A
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?